

Maria Cristina Piroso

Curriculum Vitae

Personal information

First name(s) / Surname(s)	Maria Cristina Piroso
Nationality	Italian
Date of birth	13 JUL 1986
E-mail	maria.pirosa@eoc.ch
Address	Ospedale Regionale Bellinzona e Valli, Via Gallino 12, 6500, Bellinzona
Phone number	091 811 9479

Education and training

Dates	Sep 2021-up today
Title of qualification awarded	PhD student
Name and Type of organization providing education and training	USI-Università della Svizzera Italiana (Lugano)- Prof. Dr med D. Rossi IOR Institute of Oncology Research (Switzerland)-
Dates	11Jan, 2020
Title of qualification awarded	Specialty Degree in hematology – Graduated with honours - 70/70 cum Laude,
Name and Type of organization providing education and training	University of Catania, Faculty of Medicine and Surgery (Italy)- Prof. Dr med F. Di Raimondo, Policlinico G. Rodolico, University of Catania (Italy)
Dates	14 Mar, 2013
Title of qualification awarded	Medical Doctor Degree – Graduated with honours - 110 /110 cum Laude, Thesis Title:
Name and Type of organization providing education and training	“Identificazione delle mutazioni del gene BCOR nelle leucemie acute mieloidi e studio delle sue funzioni in modelli in vitro”, Prof Dr med MP Martelli University of Perugia, Faculty of Medicine and Surgery (Italy)
Dates	2005
Title of qualification awarded	Diploma Maturità Scientifica – Grade 100/100
Name and type of organization providing education and training	“1° Istituto di Istruzione Superiore Archimede”; Liceo Scientifico, Secondary School, Rosolini (Italy)

Working experience

Dates	Jul 2021 – up today
Occupation or position held	MD Haematologist
Main activities and responsibilities	Outpatient Clinics in Lymphoma Unit
Name and address of employer	Lymphoma Unit Prof.Dr med E. Zucca, Department of Oncology, Prof. Gillessen, Oncology Institute of Southern Switzerland, Bellinzona (Switzerland)
Dates	Feb 2020 – Jun 2021
Occupation or position held	MD Haematologist
Main activities and responsibilities	Outpatient Clinics in haematology
Name and address of employer	Department of Haematology, Prof. Dr. med. Georg Stüssi, Oncology Institute of Southern Switzerland, Bellinzona (Switzerland)
Dates	Apr 2019 – Jan 2020
Occupation or position held	Resident
Main activities and responsibilities	Outpatient and Inpatient Clinics, Management of Lymphoproliferative Disorders and Chronic Myeloid Leukemia; co-investigator in phase II-III clinical trials in patients with CML
Name and address of employer	Department of Haematology, Prof. Dr med GA Palumbo, Policlinico G. Rodolico, University of Catania (Italy)
Dates	Jan 2018 – Mar 2019
Occupation or position held	Clinical Fellow
Main activities and responsibilities	Outpatients lymphoma clinics and co-investigator in phase I-III clinical trials in patients with lymphoma
Name and address of employer	Lymphoma Unit and New Drugs Prof.Dr med E. Zucca, PD. Dr med A. Stathis. Oncology Institute of Southern Switzerland, Bellinzona (Switzerland)
Dates	Jan 2015 - Dec 2017
Occupation or position held	Resident
Main activities and responsibilities	Outpatient and Inpatient Clinics, Management of Lymphoproliferative Disorders, acute leukemia, bone marrow transplantation.
Name and address of employer	Department of Haematology, Prof. Dr med F. Di Raimondo, Policlinico G. Rodolico, University of Catania (Italy)
Dates	Mar 2013- Jul 2014
Occupation or position held	Postgraduate Internship
Name and address of employer	Department of Haematology, Prof Dr med B. Falini, Ospedale Santa Maria della Misericordia, University of Perugia (Italy)

Licensure	College of Physicians Siracusa, since 2013 Swiss Recognition of medical degree (MEBEKO), in 2019 FMH in Hematology, 2020
Award(s) and recognition(s)	October 2022, "Bando giovani ricercatori", AFRI 11a Giornata della Ricerca e dell'Innovazione in Medicina Umana della Svizzera italiana, best oral presentation for the abstract "A phase-II trial of clarithromycin and lenalidomide in relapsed/refractory MALT lymphomas: IELSG40" March 2022, "Start-up IOSI" December 2020: "Bando giovani ricercatori", AFRI December 2014: "Premio Fondazione Severi", MD graduation award
Certificates	GCP certificates 2022, Introduction to Research Ethics; Research Ethics Evaluation; Informed Consent; Good Clinical Practice (GCP-E6(R2) 2016)- SAKK Investigators' Education March 2022 Certificate of competence in lymphoma (CCL4), European School of Oncology and University of Ulm , February 2019 -November 2020 CTU-Biostatistics course, November 30th and December 10th, 2020
Membership	European Hematology Association (EHA), since 2021 SAKK PG Lymphoma, since 2022
Research topic of interest	Clinical and translational research in lymphoproliferative disorders
Publication(s) <u>Peer review</u>	<p><u>Original papers</u></p> <p>Pirosa MC, Sassone M, Kiesewetter B, Guillermo AL, Devizzi L, Domènech ED, Tucci A, Mannina D, Merli M, Salar A, Visco C, Esposito F, Bonomini L, Zucca E, Ferreri AJM, Raderer M. IELSG40/CLEO phase II trial of clarithromycin and lenalidomide in relapsed/refractory extranodal marginal zone lymphoma. <i>Haematologica</i>. 2022 Dec 22. doi: 10.3324/haematol.2022.281963. Epub ahead of print. PMID: 36546422.</p> <p>Forestieri G, Terzi di Bergamo L, Deodato M, Frustaci AM, Moia R, Deambrogi C, Rasi S, Autore F, Merli M, Mattarucchi R, Fahrni G, Scarfo' L, Gussetti D, Bulian P, Zanatta A, Spina V, Brusca A, Pini K, Piffaretti D, Pirosa MC, Salehi M, Marques de Almeida J, Passweg J, Cavalli F, Zucca E, Gerber B, Stussi G, Gattei V, Ghia P, Gregor M, Passamonti F, Laurenti L, Gaidano G, Tedeschi A, Rossi D, Condoluci A. Ibrutinib dose intensity in high-risk chronic lymphocytic leukemia. <i>Hematol Oncol</i>. 2022 May 25. doi: 10.1002/hon.3032. Epub ahead of print. PMID: 35613703.</p> <p>Genta S, Ghilardi G, Cascione L, Juskevicius D, Tzankov A, Schär S, Milan L, Pirosa MC, Esposito F, Ruberto T, Giovanella L, Hayoz S, Mamot C, Dirnhofer S, Zucca E, Ceriani L. Integration of Baseline Metabolic Parameters and Mutational Profiles Predicts Long-Term Response to First-Line Therapy in DLBCL Patients: A Post Hoc Analysis of the SAKK38/07 Study. <i>Cancers (Basel)</i>. 2022 Feb 17;14(4):1018. doi: 10.3390/cancers14041018. PMID: 35205765.</p> <p>Ceriani L, Milan L, Cascione L, Gritti G, Dalmaso F, Esposito F, Pirosa MC, Schär S, Bruno A, Dirnhofer S, Giovanella L, Hayoz S, Mamot C, Rambaldi A, Chauvie S, Zucca E. Generation and validation of a PET radiomics model that predicts survival in diffuse large B cell lymphoma treated with R-CHOP14: A SAKK 38/07 trial post-hoc analysis. <i>Hematol Oncol</i>. 2021 Oct 29. doi: 10.1002/hon.2935. Epub ahead of print. PMID: 34714558.</p>

Bonfiglio F, Bruscazzin A, Guidetti F, Terzi di Bergamo L, Faderl MR, Spina V, Condoluci A, Bonomini L, Forestieri G, Koch R, Piffaretti D, Pini K, **Pirosa MC**, Cittone MG, Arribas A, Lucioni M, Ghilardi G, Wu W, Arcaini L, Baptista MJ, Bastidas G, Beà S, Boldorini R, Broccoli A, Bühler MM, Canzonieri V, Cascione L, Ceriani L, Cogliatti SB, Corradini P, Derenzini E, Devizzi L, Dietrich S, Elia AR, Facchetti F, Gaidano G, Garcia JF, Gerber B, Ghia P, Gomes da Silva M, Gritti G, Guidetti A, Hitz F, Inghirami GG, Ladetto M, López-Guillermo A, Lucchini E, Maiorana A, Marasca R, Matutes E, Meignin V, Merli M, Moccia AA, Mollejo M, Montalban C, Novak U, Oscier DG, Passamonti F, Piazza FA, Pizzolitto S, Rambaldi A, Sabattini E, Salles GA, Santambrogio E, Scarfo L, Stathis A, Stussi G, Geyer JT, Tapia G, Tarella C, Thieblemont C, Tousseyn T, Tucci A, Vanini G, Visco C, Vitolo U, Walewska R, Zaja F, Zenz T, Zinzani PL, Khiabani H, Calcinotto A, Bertoni F, Bhagat G, Campo E, de Leval L, Dirnhofer S, Pileri SA, Piris MA, Traverse-Glehen A, Tzankov A, Paulli M, Ponzoni M, Mazzucchelli L, Cavalli F, Zucca E, Rossi D. Genetic and Phenotypic Attributes of Splenic Marginal Zone Lymphoma. *Blood*. 2021 Oct 15;blood.2021012386. doi: 10.1182/blood.2021012386. Epub ahead of print. PMID: 34653238.

Bruscazzin A, Terzi di Bergamo L, Spina V, Hodgkinson B, Forestieri G, Bonfiglio F, Condoluci A, Wu W, **Pirosa MC**, Faderl MR, Koch R, Schaffer M, Alvarez JD, Fournau N, Gerber B, Stussi G, Zucca E, Balasubramanian S, Rossi D. Circulating tumor DNA for comprehensive noninvasive monitoring of lymphoma treated with ibrutinib plus nivolumab. *Blood Adv*. 2021 Sep 9;bloodadvances.2021004528. doi: 10.1182/bloodadvances.2021004528. Epub ahead of print. PMID: 34500472.

Pirosa MC, Zhang L, Hitz F, Novak U, Hess D, Terrot T, Pascale M, Mazzucchelli L, Bertoni F, Cavalli F, Zucca E, Stathis A. A phase I trial of inotuzumab ozogamicin in combination with temsirolimus in patients with relapsed or refractory CD22-positive B-cell non-Hodgkin lymphomas. *Leuk Lymphoma*. 2021 Aug 19;1-7. doi: 10.1080/10428194.2021.1966780. Epub ahead of print. PMID: 34407735.

Leotta S, Markovic U, **Pirosa MC**, Stella S, Tringali S, Martino M, Specchia G, Carluccio P, Risitano AM, Grimaldi F, Vigna E, Palmieri F, Palmieri R, Annunziata M, Pisapia G, Palazzo G, Milone GA, Pelle AC, Scalise L, Di Giorgio MA, Bulla A, Leotta V, Di Raimondo F, Milone G. The role of ponatinib in adult BCR-ABL1 positive acute lymphoblastic leukemia after allogeneic transplantation: a real-life retrospective multicenter study *Ann Hematol*. 2021 Jul;100(7):1743-1753. doi: 10.1007/s00277-021-04504-0. Epub 2021 Mar 28. PMID: 33774681

Moccia AA, Schär S, Hayoz S, **Pirosa MC**, Taverna C, Novak U, Kimby E, Ghielmini M, Zucca E. Prognostic value of POD24 validation in follicular lymphoma patients initially treated with chemotherapy-free regimens in a pooled analysis of three randomized trials of the Swiss Group for Clinical Cancer Research (SAKK). *Br J Haematol*. 2020 Aug 17. doi: 10.1111/bjh.17045.

Ceriani L, Gritti G, Cascione L, **Pirosa MC**, Polino A, Ruberto T, Stathis A, Bruno A, Moccia AA, Giovanella L, Hayoz S, Schär S, Dirnhofer S, Rambaldi A, Martinelli G, Mamot C, Zucca E. SAKK38/07 study: integration of baseline metabolic heterogeneity and metabolic tumor volume in DLBCL prognostic model. *Blood Adv*. 2020 Mar 24;4(6):1082-1092. doi: 10.1182/bloodadvances.2019001201.

Iannitto E, Romano A, Scalzulli PR, Bonanno V, Scalone R, Chiarenza A, **Pirosa MC**, Caruso AL, Minoia C, Mantuano S, De Santis G, Salerno M, Crescimanno A, Porretto F, Li Gioi F, Ricciuti G, Greco A, Pavone E, Guarini A, Tarantini G, Mannina D, Consoli U, Cascavilla N, Di Raimondo F, Musso M. Brentuximab vedotin in association with Bendamustine in refractory or multiple relapsed Hodgkin Lymphoma. A retrospective real-world study. *Eur J Haematol*. 2020 Feb 27. doi: 10.1111/ejh.13400.

Vannata B, Conconi A, Winkler J, Cascione L, Margiotta Casaluci G, Nassi L, Moia R, **Pirosa MC**, Moccia AA, Stathis A, Rossi D, Gaidano G, Zucca E. Late relapse in patients with diffuse large B-cell lymphoma: impact of rituximab on their incidence and outcome. *Br J Haematol*. 2019 Aug 5. doi: 10.1111/bjh.16106.

Romano A, Parrinello NL, La Cava P, Tibullo D, Giallongo C, Camiolo G, Puglisi F, Parisi M, **Pirosa MC**, Martino E, Conticello C, Palumbo GA, Di Raimondo F. PMN-MDSC and arginase are increased in myeloma and may contribute to resistance to therapy. *Expert Rev Mol Diagn*. 2018 Jul;18(7):675-683. doi: 10.1080/14737159.2018.1470929. Epub 2018 May 3.

Reviews

Griguolo G, Zorzi MF, **Pirosa MC**, Treglia G, Bertoni F, Kuruvilla J, Zucca E, Stathis A. A systematic review of contemporary phase I trials in patients with lymphoma. *Crit Rev Oncol Hematol*. 2022 Dec;180:103860. doi: 10.1016/j.critrevonc.2022.103860. Epub 2022 Oct 18. PMID: 36265547.

Vannata B, **Pirosa MC**, Bertoni F, Rossi D, Zucca E. Bacterial infection-driven lymphomagenesis. *Curr Opin Oncol*. 2022 Jul 26. doi: 10.1097/CCO.0000000000000886. Epub ahead of print. PMID: 35880463.

Pirosa, M.C.; Borchmann, S.; Jardin, F.; Gaidano, G.; Rossi, D. Controversies in the Interpretation of Liquid Biopsy Data in Lymphoma, *HemaSphere*: June 2022 - Volume 6 - Issue 6 - p e727. doi: 10.1097/HS9.0000000000000727

G.A. Palumbo, S. Stella, M. S. Pennisi, **M.C. Pirosà**, E. Fermo, S. Fabris, D. Cattaneo and A. Iurlo. The Role of New Technologies in Myeloproliferative Neoplasms. *Front. Oncol*. 9:321. doi: 10.3389/fonc.2019.00321. Review.

Genta S, **Pirosa MC**, Stathis A. BET and EZH2 Inhibitors: Novel Approaches for Targeting Cancer. *Curr Oncol Rep*. 2019 Feb 4;21(2):13. doi: 10.1007/s11912-019-0762-x. Review.

Case reports

Leotta S, **Pirosa MC**, Markovic U, Scalise L, Bulla A, Sapienza G, Di Giorgio MA, Martino EA, Curto Pelle A, Leotta V, Milone G, Cupri A, Vaddinelli D, Villari L, Conticello C, Milone G. Pomalidomide-Responsive Extramedullary Myeloma Relapsed after Allogeneic Hematopoietic Transplant and Refractory to Multiple Lines of Chemotherapy. *Chemotherapy*. 2019 Sep 18:1-4. doi: 10.1159/000502473. [Epub ahead of print]

E. Tirrò, M. Massimino, S. Stella, V. Zammit, M. L. Consoli, M. S. Pennisi, S. R. Vitale, C. Romano, **M. C. Pirosà**, E. Martino, S. Di Gregorio, A. Puma, F. Di Raimondo, L. Manzella and F. Stagno. Efficacy of nilotinib in a cml patient expressing the three-way complex variant translocation t(2;9;22) *Anticancer research* 39: 3893-3899 (2019) Doi:10.21873/anticancer.13540

Pirosa MC, Leotta S, Cupri A, Stella S, Martino EA, Scalise L, Sapienza G, Calafiore V, Mauro E, Spadaro A, Vigneri P, Di Raimondo F, Milone G. Long-Term Molecular Remission Achieved by Antibody Anti-CD22 and Ponatinib in a Patient Affected by Ph⁺ Acute Lymphoblastic Leukemia Relapsed after Second Allogeneic Hematopoietic Stem Cell Transplantation: A Case Report. *Chemotherapy*. 2018;63(4):220-224. doi: 10.1159/000492941. Epub 2018 Oct 29. PMID: 30372691

Oral presentations

Circulating tumor dna is a prognostic biomarker at baseline and improves the accuracy of interim pet in classic hodgkin lymphoma, abstract S225, EHA2022, Jun 09-12, 2022

Circulating tumor dna is a prognostic biomarker in classic Hodgkin lymphoma, article/abstract 070, 16-ICML, Lugano, Jun 18-22, 2021

Phase II trial of rituximab plus chlorambucil followed by a 2-year subcutaneous rituximab maintenance in malt lymphoma patients (ielsg38)article/abstract 079, 16-ICML, Lugano, Jun 18-22, 2021

Posters and Abstracts

Martina Di Trani, Francesca Ricci, Martina Sollini, Eleonora Calabretta, Vanessa Cristaldi, Stefanos Bonovas, Fabrizio Marino, Rita Mazza, Alessio Brusca, Maria Cristina Piroso, Arturo Chiti, Davide Rossi, Armando Santoro, Carmelo Carlo-Stella; Circulating Tumor DNA Integrated with Interim [18F]FDG PET Is Highly Effective in Predicting Outcome of Relapsed/Refractory Classical Hodgkin Lymphoma Treated with the Begev Regimen. *Blood* 2021; 138 (Supplement 1): 3504. doi: <https://doi.org/10.1182/blood-2021-151362>

L. Ceriani, M. Piroso, A. Stathis, G. Gritti, T. Ruberto, A. Bruno, A. Moccia, A. Rambaldi, S. Ferrari, L. Giovannella, S. Hayoz, L. Mazzucchelli, S. Dirnhofer, C. Mamot, E. Zucca, Integration between metabolic Tumour volume and metabolic heterogeneity predicts outcome of DLBCL lymphoma patients in the sakk 38/07 study cohort *Hematological Oncology*. 2019; abstract 041, 15-ICML, Lugano, Jun 18-22, 2019

A. Moccia, S. Schär, S. Hayoz, M. Piroso, C. Taverna, U. Novak, E. Kimby, M. Ghielmini, E. Zucca, Predictive value of pod24 validation in follicular lymphoma patients initially treated with chemotherapy-free regimens in a pooled analysis of three randomized trials of the swiss group for clinical cancer research (SAKK). *Hematological Oncology*. 2019; abstract 067, 15-ICML, Lugano, Jun 18-22, 2019

Marina Silvia Parisi, Valeria Calafiore, Enrica Martino, Salvatore Leotta, Maria Cristina Piroso, Giuseppe Sapienza, Vittorio Del Fabro, Alessandra Romano, Concetta Conticello, Francesco Di Raimondo. Long term disease control with pomalidomide and dexamethasone in relapsed/refractory multiple myeloma patients: a real life experience. *EHA Learning Center*. Silvia Parisi M. Jun 14, 2018; 216016

Giuseppe Milone, Annalia DiMarco, Giuseppe Sapienza, Salvatore Leotta, Luca Scalise, Carla Consoli, Maria Cristina Piroso, Alessandra Cupri, Gaetano Moschetti, Maria Grazia Camuglia, Maria Sciacca and Anna Elisa Marchese. Red Cell Distribution Width (RDW) As Prognostic Factor in Acute Leukemia Patients Undergoing Allogeneic Hematopoietic Transplantation *Blood* 2017 130:5098;

V. Calafiore, M. Parisi, V. Zammit, E. Martino, M.C. Piroso, A. Spitaleri, F. Stagno, C. Conticello, F. Di Raimondo. CSF3R T618-mutated chronic neutrophilic leukemia: a rare case successfully treated with Ruxolitinib. *EHA Learning Center*. Conticello C. May 18, 2017; 182777

V. Calafiore, E. Mauro, C. Conticello, T. Pollicino, V. Zammit, E. Spina, E. Martino, M.C. Piroso, R. Manuele, A. Imbriani, P.F. Fiumara, F. Di Raimondo *Acinetobacter baumannii* surveillance measures in haematological malignancies patients. *EHA Learning Center*. Calafiore V. Jun 12, 2015; 1000081

N. Parrinello, G. Rizzo, A. Romano, P. Fiumara, E. Mauro, M.C. Piroso, E.A. Martino, C. Giallongo, D. Tibullo, P. La Cava, A.M. Triolo, F. Di Raimondo Impaired neutrophil function in patients with acute leukemia, 45th Congress of the Italian Society of Hematology, Florence October 4-7, 2015